Warning letter
Hospira, Inc. [ARCHIVED]: warning letter of Apr 12, 2010
FDA warning letter 99786 · Atlanta District Office
Key facts
| Reference number | 99786 |
|---|---|
| Company | Hospira, Inc. [ARCHIVED] |
| Subject | CGMP for Finished Pharmaceuticals/Deviations/Adulterated |
| Issue date | Apr 12, 2010 |
| Posted date | Apr 12, 2010 |
| Issuing office | Atlanta District Office |
| Product type | Drugs |
| CFR sections cited | 211.192, 211.22(d), 211.100(a), 211.160(b), 211.165(d), 803.10(c) |
| Inspection city | Clayton |
| Inspection ZIP | 27520 |
| Inspection start date | Jan 26, 2010 |
| Letter on fda.gov | web.archive.org |
At a glance
- 1–9 CFR sections cited
- OAI Linked inspection classification
- Yes Form FDA 483 issued
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About FDA warning letters
FDA warning letters notify a firm of significant regulatory violations found during an inspection or review and request prompt corrective action.
Source: U.S. Food and Drug Administration (FDA), Warning Letters · Source date: